Stockscreener 앱 받기
0.00
100.00%
-115.07
시간 외 거래:
115.11
115.11
+
Arcellx Inc 주식(ACLX)의 최신 뉴스
OpGen Inc. (OPGN) Peer Comparison – Compare with Others - valueresearchonline.com
Arcellx (ACLX) Latest Quarter: The Available Earnings Metric Delivers a Beat in Latest Trading ; Trading Response Is Still PendingBook Value Growth - vinanet.vn
Arcellx (ACLX) Latest Quarter: EPS Exceeds Its Estimate ; Results Are Reported Without a Trading SignalPositive Surprise Momentum - vinanet.vn
7 biopharma M&A deals where layoffs followed - BioSpace
ACLX Q4 2025 Earnings: Narrower-Than-Expected Loss Reflects Clinical-Stage DisciplineProfit Margin Analysis - vinanet.vn
ACLX Q4 2025 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineRevenue Guidance Update - vinanet.vn
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - stocktwits.com
Arcellx (ACLX): Paradigm BioCapital group files 13G/A showing 0% stake - Stock Titan
ACLX Q4 2025 Earnings: Narrower-than-Expected Loss of $1.01 Per Share Underscores Clinical-Stage Focus - vinanet.vn
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Former Arcellx CFO Joins Rani Therapeutics Board After Gilead Acquisition - Stock Titan
Arcellx Q4 2025 Earnings: Narrower-Than-Expected Loss Highlights Continued Operational DisciplineBasic EPS Analysis - vinanet.vn
Gilead extends Arcellx tender offer again - MSN
Arcellx (ACLX) Holds Steady as Biotech Stock Consolidates Near SupportSector Sentiment - vinanet.vn
ACLX Q4 2025 Earnings: Narrower-than-Expected Loss Drives Modest Stock GainAnalyst Consensus Shift - vinanet.vn
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer - The National Law Review
Arcellx (ACLX) Stock Analysis: Why Arcellx (ACLX) Is Stuck at $115.07 2026-07-09Dollar Neutral Pair - dars.gov.et
Arcellx Inc. (ACLX) Holds Near Key Support Amidst ConsolidationBuyback Factor - DonanımHaber
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-than-Expected Loss, Flat Stock ReactionPost-Earnings Reaction - dars.gov.et
Arcellx (ACLX) Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseRevenue Guidance Update - dars.gov.et
How Arcellx Inc. (ACLX) Affects Rotational Strategy Timing - Stock Traders Daily
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel - The National Law Review
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
ACLX Q4 2025 Earnings: Effective Cost Management Leads to Narrower-Than-Expected LossNet Income Trends - dars.gov.et
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-than-Expected Loss on Operational EfficiencyNext Quarter Guidance - dars.gov.et
Arcellx (ACLX) Holds Near $115 as Biotech Stock Consolidates in Narrow RangeDynamic Hedging - DonanımHaber
Arcellx Inc (ACLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arcellx Inc (ACLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcellx Inc (ACLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcellx Inc (ACLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arcellx Inc. (ACLX) Holds Near Support as Consolidation ContinuesFast Moving Stocks - newsline.com
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-Than-Expected Loss Signals Operational DisciplineGuidance Update - newsline.com
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Arcellx Inc. (ACLX) Consolidates Near Key Support Level as Biotech Sector Awaits CatalystsPrice Gap Fill - newsline.com
Key facts: Gilead completes $7.8B Arcellx buy; closes Ouro Medicines deal - TradingView
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-Than-Expected Loss Signals ProgressWeak Earnings Momentum - dars.gov.et
Arcellx (ACLX) Holds Steady Near $115 as Support and Resistance Levels Define Trading RangegetLinesFromResByArray error: size == 0 - lwvtexas.org
Arcellx (ACLX) Holds Steady Near Support Amid Biotech Sector VolatilitygetLinesFromResByArray error: size == 0 - lwvtexas.org
Arcellx, Inc.Common Stock (NQ: ACLX - The Chronicle-Journal
ARCELLX Q1 2026 Earnings Preview: Recent $ACLX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Arcellx (ACLX) Amendment shows Vestal Point and Wilder report 0% ownership - Stock Titan
[15-12G] Arcellx, Inc. SEC Filing - Stock Titan
Gilead wipes out most of Arcellx workforce - BioSpace
7 months after last layoffs, Bay Area biotech giant does another round - SFGATE
Bay Area biotech takes another hit as Gilead announces major job cuts - Yahoo Finance
Gilead to lay off dozens in Rockville after closing Arcellx acquisition - The Business Journals
Rutgers axes graduation speaker after anti-Israel social media posts allegedly drew student backlash - New York Post
MSN Money - MSN
Gilead to lay off nearly 200 workers after Arcellx acquisition closes - The Business Journals
Bay Area biotech giant Gilead to lay off 108 workers in Redwood City - San Francisco Chronicle
Gilead completes Arcellx buy, securing myeloma treatment anito-cel - Rare Cancer News
Gilead Sciences Completes Acquisition of Arcellx to Strengthen Oncology Portfolio - Oncodaily
0.00%
0.81%
자본화:
|
볼륨(24시간):